Tokyo - Delayed Quote JPY

Sumitomo Pharma Co., Ltd. (4506.T)

1,884.50 -60.50 (-3.11%)

At close: October 30 at 3:30:00 PM GMT+9

Loading Chart for 4506.T

Chart Range Bar

Interval:

In partnership with ChartIQ

Sumitomo Pharma America Announces Enzomenib (DSP-5336) Receives FDA Breakthrough Therapy Designation for Treatment of R/R KMT2A-Rearranged Acute Leukemia

Sumitomo Pharma (TSE:4506) Could Be 16% Undervalued Following TWYMEEG Sales Growth

Sumitomo Pharma (TSE:4506) Stock Looks Below Fair Value On Earnings Power

Sumitomo Pharma America Announces First Patient Receives Treatment in Phase 1/2a Study for its Investigational Therapy DSP-3077 for Retinitis Pigmentosa

Sumitomo Pharma America Announces Enzomenib (DSP-5336) Receives FDA Orphan Drug Designation for Treatment of Acute Lymphoblastic Leukemia

$Sumitomo Pharma America Announces Encouraging Clinical and Translational Data at EHA 2026, Highlighting Investigational Combination Therapy in Relapsed/Refractory Myelofibrosis and New Research Findings in Menin Inhibition in Leukemia$

Sumitomo Pharma America Announces Encouraging Clinical and Translational Data at EHA 2026, Highlighting Investigational Combination Therapy in Relapsed/Refractory Myelofibrosis and New Research Findings in Menin Inhibition in Leukemia

$Sumitomo Pharma America Achieves Key Patient Enrollment Milestone for Pivotal Phase 2 Study of Enzomenib in the Treatment of Relapsed/Refractory Acute Leukemia$

Sumitomo Pharma America Achieves Key Patient Enrollment Milestone for Pivotal Phase 2 Study of Enzomenib in the Treatment of Relapsed/Refractory Acute Leukemia

Sumitomo Pharma America Presents First Clinical Data for SMP-3124LP, an Investigational PEGylated Liposome CHK1 Inhibitor, at ASCO 2026

Japan Regenerative Medicine Market Trends and Forecasts to 2035 Featuring Astellas Pharma, Fujifilm, JCR Pharmaceuticals, Sumitomo Pharma, Takeda, and Terumo

Non-Metastatic Prostate Cancer Market to Exhibit Growth at a CAGR of 4% During the Forecast Period (2026-2036), as Pharmaceutical Companies Intensify Development of Advanced Therapies | DelveInsight

Sumitomo Pharma America Announces that its Investigational Therapy DSP-3077 Has Received FDA Orphan Drug Designation for the Treatment of Retinitis Pigmentosa

U.S. markets closed